MAHALLIY TARQALGAN OSHQOZON SARATONINI ZAMONAVIY DAVOLASH
Abstrak
Oshqozon saratoni (OS) hali ham butun dunyo bo'ylab saraton bilan bog'liq o'limning yetakchi sabablaridan biri bo'lib, har yili bir milliondan ortiq yangi holatlar aniqlanadi (Smit va boshq., 2020). O'zbekistonda kasallanish buyicha OS erkaklar orasida birinchi va ayollar o'rtasida uchinchi o'rinda turadi. Mahalliy rivojlangan oshqozon saratoni (MROS), ya'ni o'simta atrofdagi to'qimalarga tarqalgan, ammo metastaz qilmagan holat, o'ziga xos davolash qiyinchiliklarini keltirib chiqaradi.
Iqtiboslar
Smith, L., Jones, M., & Wilson, A. (2020). Global trends in gastric cancer: Epidemiology, risk factors, and prevention. Cancer Epidemiology, 64, 102015.
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J., Nicolson, M., ... & Chua, Y. J. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355(1), 11-20.
Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., ... & Hofheinz, R. D. (2019). Perioperative chemotherapy with FLOT versus ECF/ECX in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, 393(10184), 1948-1957.
Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., ... & Wydra, D. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687-697.
Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., ... & Emig, M. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised trial. Lancet Oncology, 15(11), 1224-1235.
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., ... & Adelberg, D. (2018). KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated, advanced gastric or gastroesophageal junction cancer. Journal of Clinical Oncology, 36(19), 1909-1918.
